header 3
Ouch Signup
e-mail address:


First Name:

Last Name:


Home Clinical Pharma Forum

Pharma Forum

Leading international endocrinology and cardiology expert to join Irish R3i committee

Leading international consultant Professor Henry Ginsberg will visit Ireland in January 2011 for the third meeting of the Irish R3i committee. Professor Ginsberg will speak to Irish healthcare professionals to address the growing global problem of residual vascular disease.


Dual antiplatelet fixed dose combination tablet launched in Ireland

Sanofi-aventis has launched its dual antiplatelet fixed dose combination tablet, DuoPlavin, in Ireland. DuoPlavin provides a new treatment option for physicians and a more convenient alternative for patients with Acute Coronary Syndrome (ACS).


Votrient (pazopanib) receives EU conditional authorisation for advanced renal cell carcinoma

GlaxoSmithKline (GSK) recently announced that the European Commission has granted conditional marketing authorisation for Votrient (pazopanib), for the first-line treatment of advanced renal cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease. RCC is the most common type of kidney cancer.


Final analysis of ipass study confirms that Iressa is valuable option for the first-line treatment of patients with advanced NSCLC

Mature data from the IPASS study, presented at the 2010 ESMO congress (Milan), showed that overall survival (OS) was similar, with no significant difference, between Iressa (an EGFR tyrosine kinase inhibitor (TKI)) and carboplatin/paclitaxel (doublet chemotherapy) in the overall population (HR=0.90, 95 per cent CI 0.79-1.02, p=0.11, median OS 18.8 vs. 17.4 months).


New analysis demonstrates Crestor significantly reduces major cardiovascular events

A post-hoc-analysis from JUPITER published in the European Heart Journal shows Crestor (rosuvastatin) 20 mg significantly reduced major cardiovascular (CV) events, defined as the combined end-point of CV death, stroke and myocardial infarction, compared to placebo, by 50 per cent (p=0.028; CI 0.27-0.93) in high-risk patients with a 10-year Framingham risk score >20 per cent and by 43 per cent in patients with an extrapolated SCORE risk >5 per cent (p=0.0003; CI 0.32-0.68).

More Articles...
Favorite Pages
Please login first to manage your favorite pages.
IMN Poll
Is it OK to increase taxes in order to provide universal healthcare?